365 related articles for article (PubMed ID: 22536370)
21. BRAF and GNAQ mutations in melanocytic tumors of the oral cavity.
Cohen Y; Goldenberg-Cohen N; Akrish S; Shani T; Amariglio N; Dratviman-Storobinsky O; Kaplan I; Barshack I; Hirshberg A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):778-84. PubMed ID: 23159116
[TBL] [Abstract][Full Text] [Related]
22. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
23. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
[TBL] [Abstract][Full Text] [Related]
24. Frequencies of KIT and GNAQ mutations in acral melanoma.
Puntervoll HE; Molven A; Akslen LA
J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
[No Abstract] [Full Text] [Related]
25. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
[TBL] [Abstract][Full Text] [Related]
27. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
[TBL] [Abstract][Full Text] [Related]
29. Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas.
Rushton JG; Korb M; Kummer S; Reichart U; Fuchs-Baumgartinger A; Tichy A; Nell B
Vet J; 2019 Jul; 249():33-40. PubMed ID: 31239162
[TBL] [Abstract][Full Text] [Related]
30. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
31.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
32. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.
Dudley JC; Gurda GT; Tseng LH; Anderson DA; Chen G; Taube JM; Gocke CD; Eshleman JR; Lin MT
Mol Diagn Ther; 2014 Aug; 18(4):409-18. PubMed ID: 24604154
[TBL] [Abstract][Full Text] [Related]
33. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
34. Treatment implications of the emerging molecular classification system for melanoma.
Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
[TBL] [Abstract][Full Text] [Related]
35. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB; Lee JE; MacConaill LE; Palescandolo E; Van Hummelen P; Adams SM; DeAngelis MM; Hahn WC; Gragoudas ES; Harbour JW; Garraway LA; Kim IK
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6991-6. PubMed ID: 22977135
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
38. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
39. Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas.
Pappa KI; Vlachos GD; Roubelakis M; Vlachos DE; Kalafati TG; Loutradis D; Anagnou NP
Biomed Res Int; 2015; 2015():303791. PubMed ID: 25695059
[TBL] [Abstract][Full Text] [Related]
40. Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
Pisareva E; Gutkina N; Kovalenko S; Kuehnapfel S; Hartmann A; Heinzerling L; Schneider-Stock R; Lyubchenko L; Shamanin VA
Melanoma Res; 2014 Aug; 24(4):322-31. PubMed ID: 24922189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
